Effects of rapamycin on monocrotaline-induced pulmonary hypertension and pulmonary arterial remodeling in rats

doi:10.3969/j.issn.1006-7795.2013.04.015

Journal of Capital Medical University ›› 2013, Vol. 34 ›› Issue (4): 554-558.doi: 10.3969/j.issn.1006-7795.2013.04.015

Previous Articles Next Articles

Effects of rapamycin on monocrotaline-induced pulmonary hypertension and pulmonary arterial remodeling in rats

LIU Jie^1,2, DU Yuxuan^1,2, WANG Wang^1,2, GUO Huan^1,2, WANG Jun^1,2, WANG Chen^2,3

1. Department of Physiology, School of Basic Medical Science, Capital Medical University, Beijing 100069, China;
2. Beijing Key Laboratory of Respiratory and Pulmonary Circulation, Beijing 100020, China;
3. Beijing Hospital, Ministry of Health, Beijing 100730, China

Received:2013-01-15 Online:2013-08-21 Published:2013-07-20
Supported by:
This study was supported by A Grant from the Major State Basic Research Development Program of China(2009CB522107); National Natural Science Foundation of China(81070042); Major International Collaborative Research Foundation of China(30810103904); Overseas and HongKong and Macao Scholars of Collaborative Research Foundation of China(81228001); Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders(RPCD201201, 2011HXFB04); The Foundation of Scientific Research Common Program of Beijing Municipal Commission of Education(KM201310025004); Natural Science Foundation of Ningxia(NZ1220); Basis-clinical Research Co-operation Fund of Capital Medical University(12JL15).

Abstract

Abstract:

Objective To investigate the effects of rapamycin on monocrotaline(MCT)-induced pulmonary hypertension(PH) and pulmonary arterial remodeling in rats. Methods Male Sprague-Dawley rats were divided into 3 groups: control group, MCT group and rapamycin group. The right ventricular systolic pressure(RVSP) was measured via the right jugular vein catheterization into the right ventricle. The index of right ventricular hypertrophy(RVHI) was calculated. HE staining was used to assess the distal vascular remodeling. Results The body weight of MCT group was significantly lower than that of the control group; The RVSP, RVHI and the remodeling of the small arteries were significantly higher than control group. Even the body weight of rats in rapamycin group was much lower than that of the control and MCT group, while the RVSP, RVHI and the remodeling of the small arteries were significantly improved in rapamycin group compared to MCT group. Conclusion These results suggested that rapamycin could attenuate the development of pulmonary hypertension and pulmonary vascular remodeling. The results provide the theoretical basis for rapamycin to be a potential drug for treating PH.

Key words: rapamycin, monocrotaline, pulmonary hypertension, pulmonary arterial remodeling

CLC Number:

R363

LIU Jie, DU Yuxuan, WANG Wang, GUO Huan, WANG Jun, WANG Chen. Effects of rapamycin on monocrotaline-induced pulmonary hypertension and pulmonary arterial remodeling in rats[J]. Journal of Capital Medical University, 2013, 34(4): 554-558.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2013.04.015

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2013/V34/I4/554

References

[1] Nef H M, Mollmann H, Hamm C, et al. Pulmonary hypertension: updated classification and management of pulmonary hypertension[J]. Heart, 2010,96(7):552-559.

[2] Humbert M. Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology[J]. Eur Respir Rev, 2010,19(115):59-63.

[3] Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents[J]. Nat Rev Drug Discov, 2006,5(8):671-688.

[4] Terada N, Lucas J J, Szepesi A, et al. Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle[J]. J Cell Physiol, 1993,154(1):7-15.

[5] Brown E J, Albers M W, Shin T B, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex[J]. Nature, 1994,369(6483):756-758.

[6] 徐东江,朱广瑾.几种肺动脉高压相关因子的研究进展[J].中国病理生理杂志,2010,26(4):819-822.

[7] Barst R J. PDGF signaling in pulmonary arterial hypertension[J]. J Clin Invest, 2005,115(10):2691-2694.

[8] Gessler T, Seeger W, Schmehl T. Inhaled prostanoids in the therapy of pulmonary hypertension[J]. J Aerosol Med Pulm Drug Deliv, 2008,21(1):1-12.

[9] Mohacsi P J, Tuller D, Hulliger B, et al. Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor[J]. J Heart Lung Transplant, 1997,16(5):484-492.

[10] Akselband Y, Harding M W, Nelson P A. Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts[J]. Transplant Proc, 1991,23(6):2833-2836.

[11] Fajadet J, Morice M C, Bode C, et al. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial[J]. Circulation, 2005,111(8):1040-1044.

[12] Ogawa A, Firth A L, Yao W, et al. Inhibition of mTOR attenuates store-operated Ca²⁺ entry in cells from endarterectomized tissues of patients with chronic thromboembolic pulmonary hypertension[J]. Am J Physiol Lung Cell Mol Physiol, 2009,297(4):L666-L676.

[13] Deng H, Hershenson M B, Lei J, et al. Pulmonary artery smooth muscle hypertrophy: roles of glycogen synthase kinase-3beta and p70 ribosomal S6 kinase[J]. Am J Physiol Lung Cell Mol Physiol, 2010,298(6):L793-L803.

[14] 王炜,高玉环,王彬,等.雷帕霉素对人淋巴瘤Raji细胞株增殖影响及其机制的探讨[J].中华肿瘤防治杂志,2011,18(23):1843-1846.

[15] Visner G A, Lu F, Zhou H, et al. Rapamycin induces heme oxygenase-1 in human pulmonary vascular cells: Implications in the antiproliferative response to rapamycin[J]. Circulation, 2003,107(6):911-916.

[16] Wang Y, Zhao B, Zhang Y, et al. Kruppel-like factor 4 is induced by rapamycin and mediates the anti-proliferative effect of rapamycin in balloon-injured rat carotid arteries[J]. Br J Pharmacol, 2012,165(7):2378-2388.

Effects of rapamycin on monocrotaline-induced pulmonary hypertension and pulmonary arterial remodeling in rats

PDF

Knowledge

Cited

Abstract

Cite this article

share this article

References

Related Articles 12

Recommended Articles

Metrics

Comments

[1]	Fan Zhengyang, Xie Jiang, Li Fei, Wang Jingting, Patiguli·Yisilamu, Sun Dance. Factors associated with the prevalence of pulmonary hypertension in patients with sleep overlap syndrome [J]. Journal of Capital Medical University, 2020, 41(3): 482-487.
[2]	Sha Yuhui, Gao Yang, Liu Jie, Qi Xianmei, Han Lulu, Wang Wang. FSTL1 promotes proliferation, adhesion and tube formation of pulmonary artery endothelial cells [J]. Journal of Capital Medical University, 2020, 41(1): 80-86.
[3]	Qi Xianmei, Wang Lei, Zhang Ruiheng, Liu Ting, Liu Jie, Yang Ting, Wang Jun, Zhang Zhifei, Wang Chen. Rapeutic effect of MCC950 on monocrotaline induced rat pulmonary arterial hypertension and mechanism [J]. Journal of Capital Medical University, 2018, 39(6): 871-876.
[4]	Wang Jieying, Zhu Wei, Lian Shi. Topical rapamycin for the treatment of facial angiofibromas in tuberous sclerosis complex [J]. Journal of Capital Medical University, 2017, 38(5): 654-657.
[5]	Zhu Zhao, Pang Baoxing, Wu Xiaoshan, Hu Lei, Hu Liang, Wang Jinsong, Zhang Chunmei, Wang Songling. Effect of different injection doses of rapamycin on general function changes in miniature pig [J]. Journal of Capital Medical University, 2016, 37(3): 260-263.
[6]	Liu Ting, Liu Yafei, Wang Wang, Chai Sanbao, Liu Jie, Wang Jun. The effect and mechanism of glyburide on monocrotaline-induced pulmonary hypertension in rats [J]. Journal of Capital Medical University, 2015, 36(5): 723-728.
[7]	KAN Ying, WANG Tie. Comparison between pulmonary ventilation/perfusion scintigraphy and CT pulmonary angiography at different levels of embolus [J]. Journal of Capital Medical University, 2013, 34(1): 23-28.
[8]	LI Jing;WANG Chen;LIU Jie;LI Ji-feng;;LIU Yan;GU Song;YANG Yuan-hua;ZHAI Zhen-guo;GAN Hui-li;WANG Jun;. Changes of Membrane Potential in Pulmonary Smooth Muscle Cell Isolated from Chronic Thromboembolic Pulmonary Hypertension Patients [J]. Journal of Capital Medical University, 2011, 32(2): 208-213.
[9]	LI Ji-feng;WANG Chen;WANG Jun. Single Nucleotide Polymorphisms in Fibrinogen Coding Sequence and Thrombotic Diseases [J]. Journal of Capital Medical University, 2010, 31(5): 558-562.
[10]	ZHANG Ting;WANG Xiao-min. Breakthrough of the 2009 Year of 《Science》 in Life Science [J]. Journal of Capital Medical University, 2010, 31(1): 136-141.
[11]	Zhang Hong;Zhou Qiwen;Wen Shaojun;Meng Xu . Mechanism of Humoral Factor-leukocyte on Lung Injury in CHD with Severe Pulmonary Hypertension during Perioperation [J]. Journal of Capital Medical University, 2002, 23(2): 162-165.
[12]	Zhou Guangde;Chen Ruifen;Luan Liying. Changes and Role of Endothelium-derived Nitric Oxide in Experimental Pulmonary Heart Disease [J]. Journal of Capital Medical University, 2001, 22(4): 310-313.